ATE537707T1 - Lactobacillus paracasei und gewichtskontrolle - Google Patents

Lactobacillus paracasei und gewichtskontrolle

Info

Publication number
ATE537707T1
ATE537707T1 AT08156353T AT08156353T ATE537707T1 AT E537707 T1 ATE537707 T1 AT E537707T1 AT 08156353 T AT08156353 T AT 08156353T AT 08156353 T AT08156353 T AT 08156353T AT E537707 T1 ATE537707 T1 AT E537707T1
Authority
AT
Austria
Prior art keywords
lactobacillus paracasei
weight control
present
metabolic disorders
relates
Prior art date
Application number
AT08156353T
Other languages
English (en)
Inventor
Yoichi Fukushima
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Application granted granted Critical
Publication of ATE537707T1 publication Critical patent/ATE537707T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Feed For Specific Animals (AREA)
AT08156353T 2008-05-16 2008-05-16 Lactobacillus paracasei und gewichtskontrolle ATE537707T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08156353A EP2123168B1 (de) 2008-05-16 2008-05-16 Lactobacillus paracasei und Gewichtskontrolle

Publications (1)

Publication Number Publication Date
ATE537707T1 true ATE537707T1 (de) 2012-01-15

Family

ID=39591905

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08156353T ATE537707T1 (de) 2008-05-16 2008-05-16 Lactobacillus paracasei und gewichtskontrolle

Country Status (9)

Country Link
US (1) US20110268702A1 (de)
EP (2) EP2123168B1 (de)
JP (1) JP2011523407A (de)
CN (1) CN102026554B (de)
AT (1) ATE537707T1 (de)
DK (1) DK2123168T3 (de)
ES (1) ES2378839T3 (de)
PT (1) PT2123168E (de)
WO (1) WO2009138448A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI123157B (fi) * 2009-05-12 2012-11-30 Valio Oy Probioottien uusi käyttö
CN101703528B (zh) * 2009-11-25 2012-07-04 王立平 一种治疗糖尿病的复合微生物制剂及其制备方法和应用
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
TWI406665B (zh) * 2010-09-01 2013-09-01 Genmont Biotech Inc 益生菌株ｇｍ－０８０用於製備治療心臟發炎與心臟細胞凋亡之醫藥組合物及其用途
CN103156098A (zh) * 2011-12-13 2013-06-19 中国科学院烟台海岸带研究所 一种合生元食品添加剂及其制备方法
JP6067292B2 (ja) * 2012-03-19 2017-01-25 サッポロビール株式会社 セロトニン分泌促進剤
CN104413334A (zh) * 2013-08-30 2015-03-18 深圳华大基因科技有限公司 可食用组合物及其制备方法和用途
SG11201607557WA (en) * 2014-03-24 2016-10-28 Otsuka Pharma Co Ltd Novel lactobacillus paracasei strain
KR101709246B1 (ko) * 2014-05-30 2017-02-22 일동후디스 주식회사 다시마 및 복합 유산균을 이용한 항비만용 신바이오틱스 조성물
KR102125548B1 (ko) 2015-02-10 2020-06-24 주식회사 지니스 비만 억제능을 갖는 균주 및 이를 함유하는 약학 조성물
US10632165B2 (en) 2016-01-18 2020-04-28 Academia Sinica Beneficial effect of Bidens pilosa on fat decrease and muscle increase
JP6813974B2 (ja) * 2016-07-14 2021-01-13 株式会社明治 グレリン分泌促進剤
KR101924048B1 (ko) 2016-08-05 2018-11-30 (주)아마존허브 발효 혼합 식이섬유 유산균 제조방법
CN106306969A (zh) * 2016-08-30 2017-01-11 牛婷婷 一种保健营养品红豆粉的制备方法
CN106343370A (zh) * 2016-08-30 2017-01-25 牛婷婷 一种保健营养品豌豆粉的制备方法
CN106343369A (zh) * 2016-08-30 2017-01-25 牛婷婷 一种保健营养品大豆粉的制备方法
US20200270709A1 (en) * 2017-04-06 2020-08-27 Korea Food Research Institute Novel Strain Having Activity Of Reducing Advanced Glycation End Products And Use Thereof
TWI651412B (zh) * 2017-11-01 2019-02-21 葡萄王生技股份有限公司 用於改善代謝症候群的新穎副乾酪乳桿菌gks6、其培養基、培養方法、用途、醫藥組合物及可食用組合物
CN109744441A (zh) * 2017-11-02 2019-05-14 健茂生物科技股份有限公司 具抗氧化功能的仙人掌果与红龙果复合发酵饮品的制备工艺
CN111954536A (zh) * 2018-03-23 2020-11-17 森永乳业株式会社 用于预防学龄期及之后的高血糖引起的疾病的婴幼儿用组合物
TWI739078B (zh) * 2018-04-25 2021-09-11 日商曾根農場股份有限公司 脂肪累積抑制用組成物
CN111164201B (zh) * 2018-07-02 2023-09-12 葡萄王生技股份有限公司 用于改善代谢症候群的副干酪乳杆菌gks6、其用途、医药组合物及可食用组合物
JP2019022520A (ja) * 2018-10-19 2019-02-14 株式会社東洋新薬 組成物
CN109924506B (zh) * 2019-03-04 2021-06-04 山东环亿生物科技有限公司 一种具有减肥功能的益生菌组合物及其制备方法和应用
US11202812B2 (en) 2019-03-29 2021-12-21 Tci Co., Ltd. Reducing body fat probiotic strain, composition thereof, and use thereof
CN110638844A (zh) * 2019-10-22 2020-01-03 江苏恒丰强生物技术有限公司 一种预防宠物2型糖尿病的复合微生态制剂及其应用
KR102537991B1 (ko) * 2020-10-13 2023-05-30 경북대학교 산학협력단 돼지 체중 증가용 조성물 및 이의 용도
TWI797769B (zh) * 2021-10-06 2023-04-01 樂牧生技股份有限公司 副乾酪乳酸桿菌lm-141分離株及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115050A (en) * 1995-10-16 2003-03-31 Mead Johnson Nutrition Co Diabetic nutritional product having controlled absorption of carbohydrate
JP2003527432A (ja) * 2000-03-24 2003-09-16 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 腹膜炎の治療のための乳酸菌の使用
KR100356672B1 (ko) 2001-12-27 2002-10-19 주식회사 바이로박트 신규한 락토바실러스 속 미생물 및 그 용도
US7001756B1 (en) 2004-02-19 2006-02-21 Genmont Biotech Inc. Microorganism strain of GM-020 of Lactobacillus rhamnosus and its use for treating obesity
CN100396770C (zh) 2004-03-19 2008-06-25 景岳生物科技股份有限公司 新的微生物鼠李糖乳杆菌gm-020及其治疗肥胖的用途
EP1855550B1 (de) * 2005-02-28 2011-10-05 N.V. Nutricia Nährstoffzusammensetzung mit probiotika
ITMI20051510A1 (it) 2005-08-02 2007-02-03 Proge Farm Srl Uso di specifici batteri lattici per la preparazione di composizioni iunomodulanti
SE529185C2 (sv) * 2005-10-07 2007-05-22 Arla Foods Amba Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
PL1981516T3 (pl) * 2006-01-27 2019-03-29 Dupont Nutrition Biosciences Aps Zastosowanie mikroorganizmów probiotycznych w leczeniu i zapobieganiu otyłości i pokrewnym zaburzeniom

Also Published As

Publication number Publication date
US20110268702A1 (en) 2011-11-03
PT2123168E (pt) 2012-03-28
EP2123168B1 (de) 2011-12-21
EP2296489A1 (de) 2011-03-23
DK2123168T3 (da) 2012-04-10
CN102026554A (zh) 2011-04-20
ES2378839T3 (es) 2012-04-18
EP2123168A1 (de) 2009-11-25
JP2011523407A (ja) 2011-08-11
CN102026554B (zh) 2013-11-06
WO2009138448A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
ATE537707T1 (de) Lactobacillus paracasei und gewichtskontrolle
HRP20181353T1 (hr) Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
MX2011008398A (es) Lactobacillus helveticus cncm i-4095 y el control del peso.
EP2650002A4 (de) Bifidobacterium cect 7765 und seine verwendung bei der vorbeugung und/oder behandlung von übergewicht, adipositas und ähnlichen krankheitsbildern
IL213168A0 (en) 1,2,4-oxadiazole derivatives and their therapeutic use
WO2008053444A3 (en) Treating a respiratory condition with bifidobacterium
CL2012000487A1 (es) Composicion que comprende bifidobacterium longum baa-999 para tratar y/o prevenir trastornos gi funcionales.
MX2011008399A (es) Lactobacillus rhamnosus ncc4007, una mezcla probiotica y el control del peso.
HK1199031A1 (en) Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof 2--5--1,2,4-
MY155516A (en) Lactobacillus rhamnosus and weight control
DK2385837T3 (da) Sammensætninger omfattende probiotiske og præbiotiske bestanddele og mineralsalte, med lactoferrin
BRPI0812452A2 (pt) Meio de distribuição com ajustador de dose travável e válvula de uma via
PL2276498T3 (pl) Zastosowanie bakterii probiotycznych do leczenia hiperhomocysteinemii
ZA201109086B (en) Prevention and treatment of allergic diarrhoea
EP2155705A4 (de) Zusammensetzungen zur regulierung oder modulierung eines quorum-sensings in bakterien, verfahren zur verwendung der verbindungen und verfahren zur regulierung oder modulierung eines quorum-sensings in bakterien
IL200570A0 (en) Combination therapy, composition and methods for the treatment of cardiovascular disorders
IL202523A0 (en) Buspirone for the treatment of mausea and vomiting
ATE531715T1 (de) 1,3-dihydro-2h-pyrroloä3.2-büpyridin-2-onderiva e,deren herstellung und deren therapeutische verwendungen
EP2266619A4 (de) Pharmazeutische zusammensetzung auf basis eines leberschützenden mittels und eines präbiotischen mittels, ihre herstellung und verwendung
AP2010005435A0 (en) 1,4-Naphthoquinone derivatives and therapeutic usethereof.
HK1130663A1 (en) Use of micron-sized sulphur for the prevention and treatment of pathogenic disorders in humans and animals
JO2662B1 (en) Use of 4-methoxy-cyclopropyl-5, 3-N-dichloro-1-oxoperidine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of spinal cord injuries
TH0801004134A (th) Lactobacillus rhamnosus และการควบคุมน้ำหนัก
AU313911S (en) Device for treating muscles
PL383872A1 (pl) Sposób regulacji amplitudy drgań, zwłaszcza w urządzeniach stosowanych w rehabilitacji i treningu